BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

338 related articles for article (PubMed ID: 27146067)

  • 1. (18)F-FDG PET/CT imaging in rectal cancer: relationship with the RAS mutational status.
    Lovinfosse P; Koopmansch B; Lambert F; Jodogne S; Kustermans G; Hatt M; Visvikis D; Seidel L; Polus M; Albert A; Delvenne P; Hustinx R
    Br J Radiol; 2016 Jul; 89(1063):20160212. PubMed ID: 27146067
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FDG PET/CT radiomics for predicting the outcome of locally advanced rectal cancer.
    Lovinfosse P; Polus M; Van Daele D; Martinive P; Daenen F; Hatt M; Visvikis D; Koopmansch B; Lambert F; Coimbra C; Seidel L; Albert A; Delvenne P; Hustinx R
    Eur J Nucl Med Mol Imaging; 2018 Mar; 45(3):365-375. PubMed ID: 29046927
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Accuracy of F-18 FDG PET/CT with optimal cut-offs of maximum standardized uptake value according to size for diagnosis of regional lymph node metastasis in patients with rectal cancer.
    Bae SU; Won KS; Song BI; Jeong WK; Baek SK; Kim HW
    Cancer Imaging; 2018 Sep; 18(1):32. PubMed ID: 30217167
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CT texture analysis compared to Positron Emission Tomography (PET) and mutational status in resected melanoma metastases.
    Olthof SC; Krumm P; Weichold O; Eigentler T; Bösmüller H; la Fougère C; Pfannenberg C; Martus P; Klumpp B
    Eur J Radiol; 2020 Oct; 131():109242. PubMed ID: 32942199
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relationship Between 18F-FDG PET/CT Scans and KRAS Mutations in Metastatic Colorectal Cancer.
    Kawada K; Toda K; Nakamoto Y; Iwamoto M; Hatano E; Chen F; Hasegawa S; Togashi K; Date H; Uemoto S; Sakai Y
    J Nucl Med; 2015 Sep; 56(9):1322-7. PubMed ID: 26135109
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Correlation between
    Liu X; Wang SC; Ni M; Xie Q; Zhang YF; Lv WF; Geng GY
    Abdom Radiol (NY); 2022 Apr; 47(4):1255-1264. PubMed ID: 35138462
    [TBL] [Abstract][Full Text] [Related]  

  • 7. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prediction of neoadjuvant radiation chemotherapy response and survival using pretreatment [(18)F]FDG PET/CT scans in locally advanced rectal cancer.
    Bang JI; Ha S; Kang SB; Lee KW; Lee HS; Kim JS; Oh HK; Lee HY; Kim SE
    Eur J Nucl Med Mol Imaging; 2016 Mar; 43(3):422-31. PubMed ID: 26338180
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relationship between 18F-fluorodeoxyglucose accumulation and KRAS/BRAF mutations in colorectal cancer.
    Kawada K; Nakamoto Y; Kawada M; Hida K; Matsumoto T; Murakami T; Hasegawa S; Togashi K; Sakai Y
    Clin Cancer Res; 2012 Mar; 18(6):1696-703. PubMed ID: 22282467
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prediction of tumor response after neoadjuvant chemoradiotherapy in rectal cancer using (18)fluorine-2-deoxy-D-glucose positron emission tomography-computed tomography and serum carcinoembryonic antigen: a prospective study.
    Li QW; Zheng RL; Ling YH; Wang QX; Xiao WW; Zeng ZF; Fan W; Li LR; Gao YH
    Abdom Radiol (NY); 2016 Aug; 41(8):1448-55. PubMed ID: 27116012
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The value of
    Oner AO; Budak ES; Yıldırım S; Aydın F; Sezer C
    Hell J Nucl Med; 2017; 20(2):160-165. PubMed ID: 28697193
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lack of association between KRAS mutations and 18F-FDG PET/CT in Caucasian metastatic colorectal cancer patients.
    Krikelis D; Skoura E; Kotoula V; Rondogianni P; Pianou N; Samartzis A; Xanthakis I; Fountzilas G; Datseris IE
    Anticancer Res; 2014 May; 34(5):2571-9. PubMed ID: 24778079
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Value of combined multiparametric MRI and FDG-PET/CT to identify well-responding rectal cancer patients before the start of neoadjuvant chemoradiation.
    Schurink NW; Min LA; Berbee M; van Elmpt W; van Griethuysen JJM; Bakers FCH; Roberti S; van Kranen SR; Lahaye MJ; Maas M; Beets GL; Beets-Tan RGH; Lambregts DMJ
    Eur Radiol; 2020 May; 30(5):2945-2954. PubMed ID: 32034488
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of sequential 18(F) -FDG PET/CT in predicting tumour response after preoperative chemoradiation for rectal cancer.
    Sun W; Xu J; Hu W; Zhang Z; Shen W
    Colorectal Dis; 2013 May; 15(5):e231-8. PubMed ID: 23384167
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diagnostic value of FDG-PET/CT for lateral pelvic lymph node metastasis in rectal cancer treated with preoperative chemoradiotherapy.
    Ishihara S; Kawai K; Tanaka T; Kiyomatsu T; Hata K; Nozawa H; Morikawa T; Watanabe T
    Tech Coloproctol; 2018 May; 22(5):347-354. PubMed ID: 29623475
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lymph node standardized uptake values at pre-treatment
    Jeong Y; Baek S; Park JW; Joo JH; Kim JS; Lee SW
    Br J Radiol; 2017 Mar; 90(1071):20160239. PubMed ID: 28008776
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Imaging prediction of
    Wu KC; Chen SW; Hsieh TC; Yen KY; Chang CJ; Kuo YC; Hsu YJ; Chang RF; Kao CH
    Br J Radiol; 2023 Nov; 96(1151):20230243. PubMed ID: 37750945
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment of biological parameters in head and neck cancer based on in vivo distribution of
    Cegla P; Kazmierska J; Gwozdz S; Czepczynski R; Malicki J; Cholewinski W
    Tumori; 2020 Feb; 106(1):33-38. PubMed ID: 31446858
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic utility of serial
    Fernando S; Lin M; Pham TT; Chong S; Ip E; Wong K; Chua W; Ng W; Lin P; Lim S
    Br J Radiol; 2020 Jan; 93(1105):20190455. PubMed ID: 31617737
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Do clinical, histological or immunohistochemical primary tumour characteristics translate into different (18)F-FDG PET/CT volumetric and heterogeneity features in stage II/III breast cancer?
    Groheux D; Majdoub M; Tixier F; Le Rest CC; Martineau A; Merlet P; Espié M; de Roquancourt A; Hindié E; Hatt M; Visvikis D
    Eur J Nucl Med Mol Imaging; 2015 Oct; 42(11):1682-1691. PubMed ID: 26140849
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.